Related Experiment Video
Updated: Nov 24, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Locoregional therapies in patients with recurrent intrahepatic cholangiocarcinoma after curative resection
Hsiao-Tien Liu1, Shao-Bin Cheng2, Chia-Yu Lai2
1Department of Surgery, Taichung Veterans General Hospital, 1650 Boulevard Sect. 4, Taichung, 40705, R.O.C School of Medicine, Chung Shan Medical University, Taichung.
Background:
Hepatectomy is one potential treatment for intrahepatic cholangiocarcinoma (IHCC). Recurrent rate is high after curative resection and most recurrences occur within residual liver parenchyma. The aim of this study was to elucidate the impact of different treatment modalities on recurrent diseases in patients with IHCC after primary liver resection.
Methods:
Between February 1999 and December 2015, we retrospectively identified patients who received curative resection for IHCC. Patients who experienced recurrences were included. Locoregional therapies included re-hepatectomy, radiofrequent ablation, and transhepatic arterial chemoembolization. These patients were categorized into three groups: intrahepatic recurrence without locoregional therapies (group A), intrahepatic recurrence with locoregional therapies (group B) and extrahepatic metastases (group C).
Results:
Forty-three patients were included and there were 12, 15, and 16 patients in groups A, B, and C, respectively. The median disease-free survival times were 8.3, 9.1, and 8.7 months in groups A, B, and C (p = 0.099). The median after-recurrence overall survival times (period between recurrence and death/censor) were 6.4, 34.0, and 8.3 months in groups A, B, and C (p = 0.001). Locoregional therapies showed favorable benefit in multivariant analysis (hazard ratio: 0.274, confidence interval: 0.083-0.908, p = 0.010).
Conclusion:
Locoregional therapies offered favorable benefits for patients with recurrent intrahepatic cholangiocarcinoma.
